Select a community
MS
Find out more about the PatientsLikeMe
MS Community
Home > Community Treatment Reports > Montelukast Treatment Report
What is Montelukast?

Montelukast is in a class of medications called leukotriene receptor antagonists (LTRAs). It works by blocking the action of substances in the body that cause the symptoms of asthma and allergies. Read more...Click to read more below

Reasons taken & Efficacy

Reasons and Efficacy
Reasons taken # of patients Major Moderate Slight None Can’t tell # of patients evaluated by
Asthma 28 3
Other 23 4
Allergies 15 1
General health 4 0
severe itching 2 0
Support another treatment 1 0

Mouse over the table for more information

Side Effects

Side effects as an overall problem

Severe
0 0%
Moderate
0 0%
Mild
0 0%
None
8 100%

Dosages

  daily 1 mg daily 4 mg daily 10 mg daily
  6 Number of Patients: 6 1 Number of Patients: 1 4 Number of Patients: 4 60 Number of Patients: 60  

Stop Reasons

Why Patients Stopped Taking Montelukast (multiple reasons could be selected)
Reason # Patients Percentage of patients
Expense
4 40% Expense: 40%
Did not seem to work
2 20% Did not seem to work: 20%
Course of treatment ended
2 20% Course of treatment ended: 20%
Personal research
1 10% Personal research: 10%
Doctor's advice
1 10% Doctor's advice: 10%
Other
1 10% Other: 10%

See all 10 patients who’ve stopped taking Montelukast

Currently Taking Montelukast

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
1
1
2
5
12
20

Stopped Taking Montelukast

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
1
1
1
3
1
3

Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Always
8 100%
Usually
0 0%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
0 0%
Somewhat
0 0%
A little
1 13%
Not at all
7 88%

Cost

Paid out of pocket

$200+
0 0%
$100-199
1 13%
$50-99
0 0%
$25-49
0 0%
< $25
2 25%

See more information, including instructions, precautions, side effects, and interactions.

Report created on November 22, 2009.